Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Enzalutamide or Abiraterone Acetate With Prednisone in the Treatment of Metastatic Castration-resistant Prostate Cancer in Real-life Clinical Practice: A Long-term Single Institution Experience

O. Fiala, P. Hosek, H. Korunkova, M. Hora, J. Kolar, J. Windrichova, O. Sorejs, O. Topolcan, I. Travnicek, H. Sedlackova, J. Finek

. 2023 ; 43 (1) : 463-471. [pub] -

Language English Country Greece

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc23004717

BACKGROUND/AIM: Enzalutamide (ENZ) and abiraterone acetate with prednisone (AAP) represent novel hormonal therapies used in the treatment of metastatic castration-resistant prostate cancer (mCRPC). The aim of the study was to assess the long-term outcome of mCRPC patients treated with ENZ or AAP in real-life clinical practice. PATIENTS AND METHODS: The outcomes of 337 mCRPC patients treated with ENZ or AAP were retrospectively analysed. RESULTS: Median radiographic progression-free (rPFS) and overall survival (OS) of patients treated in the first line (pre-chemotherapy) was 13.89 (95% CI=12.40-16.80) and 31.02 (95% CI=24.27-37.44) months vs. 10.97 (95% CI=8.97-14.82) and 26.57 (95% CI=15.97-33.92) months for those treated in the second line (post-chemotherapy). We found inferior survival for patients with synchronous metastases, high Gleason score (GS) and visceral metastases. CONCLUSION: The efficacy of both ENZ and AAP in mCRPC patients is herein confirmed. Synchronous metastases, high GS and visceral metastases were identified as significant adverse prognostic factors.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23004717
003      
CZ-PrNML
005      
20230425171657.0
007      
ta
008      
230418s2023 gr f 000 0|eng||
009      
AR
024    7_
$a 10.21873/anticanres.16183 $2 doi
035    __
$a (PubMed)36585174
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Fiala, Ondrej $u Department of Oncology and Radiotherapeutics, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic; fialao@fnplzen.cz $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
245    10
$a Enzalutamide or Abiraterone Acetate With Prednisone in the Treatment of Metastatic Castration-resistant Prostate Cancer in Real-life Clinical Practice: A Long-term Single Institution Experience / $c O. Fiala, P. Hosek, H. Korunkova, M. Hora, J. Kolar, J. Windrichova, O. Sorejs, O. Topolcan, I. Travnicek, H. Sedlackova, J. Finek
520    9_
$a BACKGROUND/AIM: Enzalutamide (ENZ) and abiraterone acetate with prednisone (AAP) represent novel hormonal therapies used in the treatment of metastatic castration-resistant prostate cancer (mCRPC). The aim of the study was to assess the long-term outcome of mCRPC patients treated with ENZ or AAP in real-life clinical practice. PATIENTS AND METHODS: The outcomes of 337 mCRPC patients treated with ENZ or AAP were retrospectively analysed. RESULTS: Median radiographic progression-free (rPFS) and overall survival (OS) of patients treated in the first line (pre-chemotherapy) was 13.89 (95% CI=12.40-16.80) and 31.02 (95% CI=24.27-37.44) months vs. 10.97 (95% CI=8.97-14.82) and 26.57 (95% CI=15.97-33.92) months for those treated in the second line (post-chemotherapy). We found inferior survival for patients with synchronous metastases, high Gleason score (GS) and visceral metastases. CONCLUSION: The efficacy of both ENZ and AAP in mCRPC patients is herein confirmed. Synchronous metastases, high GS and visceral metastases were identified as significant adverse prognostic factors.
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé $7 D006801
650    12
$a abirateron $x terapeutické užití $7 D000069501
650    _2
$a prednison $x terapeutické užití $7 D011241
650    12
$a nádory prostaty rezistentní na kastraci $x patologie $7 D064129
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a nitrily $7 D009570
650    _2
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
700    1_
$a Hosek, Petr $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Korunkova, Hana $u Department of Oncology and Radiotherapeutics, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Hora, Milan $u Department of Urology, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Kolar, Jiri $u Department of Urology, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Windrichova, Jindra $u Department of Immunochemistry Diagnostics, University Hospital in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Sorejs, Ondrej $u Department of Oncology and Radiotherapeutics, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Topolcan, Ondrej $u Department of Immunochemistry Diagnostics, University Hospital in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Travnicek, Ivan $u Department of Urology, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Sedlackova, Hana $u Department of Urology, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Finek, Jindrich $u Department of Oncology and Radiotherapeutics, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic
773    0_
$w MED00000478 $t Anticancer research $x 1791-7530 $g Roč. 43, č. 1 (2023), s. 463-471
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36585174 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230418 $b ABA008
991    __
$a 20230425171654 $b ABA008
999    __
$a ok $b bmc $g 1925042 $s 1190926
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 43 $c 1 $d 463-471 $e - $i 1791-7530 $m Anticancer research $n Anticancer Res $x MED00000478
LZP    __
$a Pubmed-20230418

Find record

Citation metrics

Archiving options